
If you have hereditary ATTR amyloidosis, there's a 50% chance of passing it to your children.
The HSE have reversed a decision not to reimburse people for a drug for those with a rare condition that causes nerve damage.
Hereditary ATTR amyloidosis, has a specific Irish variant and can be passed on genetically.
Amvuttra is a new treatment that would only need to be administered 4 times a year, rather than the 17 times required currently.
Last year, the Health Service decided the drug would not be reimbursed, however, that decision has been reversed subject to a managed access protocol.
Fianna Fáil Longford Westmeath TD, Joe Flaherty says it's an important move: